Advertisement

Topics

Long-term Safety and Efficacy Extension Study Data of ALPROLIX® for Hemophilia B Published in Thrombosis and Haemostasis

07:00 EST 2 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Median prophylactic dosing interval of 13.7 days in 86% of adult/adolescent subjects in individualized ALPROLIX treatment group Long-term safety and low annual bleed rate maintained in longest study of an extended half-...

Other Sources for this Article

BIOVERATIV
Media Contact:
Tracy Vineis, +1 781-663-4350
media@bioverativ.com
or
Investor Relations Contact:
Susan Altschuller, +1 781-663-4360
IR@bioverativ.com
or
SOBI
Media Contact:
Linda Holmström, + 46 708 73 40 95
linda.holmstrom@sobi.com
or
Investor Relations Contact:
Jörgen Winroth, +1 347-224-0819
jorgen.winroth@sobi.com

NEXT ARTICLE

More From BioPortfolio on "Long-term Safety and Efficacy Extension Study Data of ALPROLIX® for Hemophilia B Published in Thrombosis and Haemostasis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Recombinant DNA
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...

Stroke - Cerebrovascular Disease (CVA)
A stroke is a serious medical condition that occurs when the blood supply to part of the brain is cut off. Strokes are a medical emergency and prompt treatment is essential because the sooner a person receives treatment for a stroke, the less damage is ...